Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
October 03, 2022 06:30 ET
|
Axsome Therapeutics, Inc.
Statistically significant improvement in cognitive function, as measured by the DSST RBANS compared to placebo (p=0.009, primary endpoint) Statistically significant patient-reported improvement in...
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
September 29, 2022 07:28 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
September 21, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit
September 14, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
September 08, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research
September 07, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor
September 01, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
August 19, 2022 06:45 ET
|
Axsome Therapeutics, Inc.
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week1-4 AUVELITY...
Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and...